BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23094755)

  • 21. Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease.
    Stinton LM; Loomba R
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):5-13. PubMed ID: 24632764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology and natural history of non-alcoholic fatty liver disease.
    Fazel Y; Koenig AB; Sayiner M; Goodman ZD; Younossi ZM
    Metabolism; 2016 Aug; 65(8):1017-25. PubMed ID: 26997539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
    Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
    Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
    Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease.
    Petta S; Handberg A; Craxì A
    Curr Pharm Des; 2013; 19(29):5193-218. PubMed ID: 23394090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and Severity of Nonalcoholic Fatty Liver Disease Among Caregivers of Patients With Nonalcoholic Fatty Liver Disease Cirrhosis.
    Siddiqui MS; Carbone S; Vincent R; Patel S; Driscoll C; Celi FS; Billingsley H; Rotelli B; John B; Potere N; Viscusi M; Adiletta V; Sanyal AJ; Luketic VA; Reichman T; Bhati CS
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2132-2133. PubMed ID: 30448600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter?
    Domanski JP; Park SJ; Harrison SA
    J Clin Gastroenterol; 2012; 46(5):427-30. PubMed ID: 22469639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive.
    Wieckowska A; Feldstein AE
    Semin Liver Dis; 2008 Nov; 28(4):386-95. PubMed ID: 18956295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.